MOHSIN UL MULK

• Progressive roles across QC, QA, Pharmacovigilance and R&D
• Operational Excellence Achievements
• Led company-wide process optimization programme reducing average testing & release cycle time by 28% and delivering significant increases in operational efficiency and cost savings.
• Built & rolled out a real-time KPI dashboard enabling senior management to track deviations, complaints and lab productivity, improving decision-making speed by 35%.
• Conducted 5S and Kaizen events in labs & support areas, reducing space wastage by 30% and improving staff productivity by 18%.
• Standardized analytical testing workflows across 3 labs, decreasing sample backlog by 40% and error rates by 25%.
• Implemented risk-based sampling & automated reporting, saving ~200 man-hours per month.
• Directed root-cause analysis and CAPA projects that cut repeat deviations by 45%, boosting GMP audit scores from 80% to 95%.
• Harmonized 150+ SOPs across multiple sites, slashing training time for new staff by 30%.
• Redesigned adverse-event reporting workflow to meet global timelines, reducing reporting turnaround by 32% and improving regulatory compliance rating to “Excellent.”
• Launched integrated cross-departmental safety response channels reducing escalation time from 3 days to
• Co-implemented Quality by Design (QbD) in new product development, reducing scale-up deviations by 20% and time-to-market for new molecules by 15%.
• Developed structured templates & workflows for knowledge transfer from R&D to production, cutting tech-transfer issues by 25%.
• Key Projects
• Lean Laboratory Transformation: Cut QC testing cycle time by 28%, achieved significant increases in staff utilization (18%)
• Deviation Prevention Program: Achieved 45% reduction in repeat deviations across QA & manufacturing
• Integrated Safety Dashboard: Improved pharmacovigilance response time from 72 h to
• QbD Implementation Initiative: Reduced scale-up failures by 20%, shortened product launch timelines by 15%

Key Projects

• Lean Laboratory Transformation: Cut QC testing cycle time by 28%, achieved significant increases in staff utilization (18%)

• Deviation Prevention Program: Achieved 45% reduction in repeat deviations across QA & manufacturing

• Integrated Safety Dashboard: Improved pharmacovigilance response time from 72 h to

• QbD Implementation Initiative: Reduced scale-up failures by 20%, shortened product launch timelines by 15%